(TMHC) Taylor Morn Home - Ratings and Ratios
Homes, Developments, Communities, Properties
TMHC EPS (Earnings per Share)
TMHC Revenue
Description: TMHC Taylor Morn Home
Taylor Morrison Home Corporation is a leading US homebuilder and land developer, operating across multiple states with a diverse portfolio of brands, including Taylor Morrison, Darling Homes Collection, and Esplanade. The company designs, builds, and sells a range of homes, from single-family detached homes to multi-family attached homes, and develops master-planned communities and multi-use properties.
The companys business model is diversified across various segments, including homebuilding, land development, and financial services, such as title insurance and closing settlement services. Taylor Morrison Home Corporation also has a presence in the build-to-rent market through its Yardly brand. With operations in 13 states, the company has a significant geographic footprint, allowing it to capitalize on regional market trends.
From a financial perspective, Taylor Morrison Home Corporation has demonstrated a strong return on equity (RoE) of 15.75%, indicating efficient use of shareholder capital. The companys price-to-earnings (P/E) ratio is 7.24, which is relatively low compared to its peers, suggesting potential undervaluation. Additionally, the companys market capitalization is approximately $6.24 billion, indicating a significant market presence.
To further analyze the companys performance, key performance indicators (KPIs) such as revenue growth, gross margin, and homebuilding margins can be examined. For instance, the companys revenue growth rate, average selling price (ASP) of homes, and gross margin percentage can provide insights into its operational efficiency and pricing power. Furthermore, metrics such as land holdings, lot count, and community count can help assess the companys growth prospects and ability to execute its business plan.
TMHC Stock Overview
| Market Cap in USD | 6,884m |
| Sub-Industry | Homebuilding |
| IPO / Inception | 2013-04-10 |
TMHC Stock Ratings
| Growth Rating | 45.7% |
| Fundamental | 64.7% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -16.4% |
| Analyst Rating | 4.30 of 5 |
TMHC Dividends
Currently no dividends paidTMHC Growth Ratios
| Growth Correlation 3m | 82.1% |
| Growth Correlation 12m | -38.8% |
| Growth Correlation 5y | 88.4% |
| CAGR 5y | 41.39% |
| CAGR/Max DD 3y | 1.48 |
| CAGR/Mean DD 3y | 7.08 |
| Sharpe Ratio 12m | -0.34 |
| Alpha | 0.00 |
| Beta | 0.975 |
| Volatility | 33.33% |
| Current Volume | 1164.4k |
| Average Volume 20d | 1164.4k |
| Stop Loss | 66.2 (-3%) |
| Signal | -0.21 |
Piotroski VR‑10 (Strict, 0-10) 5.5
| Net Income (903.3m TTM) > 0 and > 6% of Revenue (6% = 504.2m TTM) |
| FCFTA 0.05 (>2.0%) and ΔFCFTA -3.30pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 73.61% (prev 82.07%; Δ -8.47pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.06 (>3.0%) and CFO 525.4m <= Net Income 903.3m (YES >=105%, WARN >=100%) |
| Net Debt (-55.8m) to EBITDA (1.29b) ratio: -0.04 <= 3.0 (WARN <= 3.5) |
| Current Ratio 11.35 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (102.0m) change vs 12m ago -4.88% (target <= -2.0% for YES) |
| Gross Margin 24.11% (prev 24.00%; Δ 0.10pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 90.60% (prev 81.18%; Δ 9.43pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 39.80 (EBITDA TTM 1.29b / Interest Expense TTM 31.5m) >= 6 (WARN >= 3) |
Altman Z'' 8.35
| (A) 0.65 = (Total Current Assets 6.78b - Total Current Liabilities 597.5m) / Total Assets 9.45b |
| (B) 0.51 = Retained Earnings (Balance) 4.80b / Total Assets 9.45b |
| (C) 0.14 = EBIT TTM 1.26b / Avg Total Assets 9.27b |
| (D) 1.42 = Book Value of Equity 4.80b / Total Liabilities 3.39b |
| Total Rating: 8.35 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 64.65
| 1. Piotroski 5.50pt = 0.50 |
| 2. FCF Yield 5.49% = 2.75 |
| 3. FCF Margin 5.83% = 1.46 |
| 4. Debt/Equity 0.36 = 2.44 |
| 5. Debt/Ebitda 1.68 = 0.62 |
| 6. ROIC - WACC (= 4.61)% = 5.76 |
| 7. RoE 15.33% = 1.28 |
| 8. Rev. Trend 4.49% = 0.34 |
| 9. EPS Trend -9.74% = -0.49 |
What is the price of TMHC shares?
Over the past week, the price has changed by -2.50%, over one month by +0.21%, over three months by +16.49% and over the past year by -0.80%.
Is Taylor Morn Home a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of TMHC is around 80.15 USD . This means that TMHC is currently undervalued and has a potential upside of +17.44% (Margin of Safety).
Is TMHC a buy, sell or hold?
- Strong Buy: 4
- Buy: 5
- Hold: 1
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the TMHC price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 76 | 11.4% |
| Analysts Target Price | 76 | 11.4% |
| ValueRay Target Price | 88.5 | 29.7% |
Last update: 2025-09-15 04:45
TMHC Fundamental Data Overview
CCE Cash And Equivalents = 130.2m USD (Cash And Short Term Investments, last quarter)
P/E Trailing = 8.052
P/E Forward = 10.989
P/S = 0.8192
P/B = 1.1384
P/EG = 1.511
Beta = 1.586
Revenue TTM = 8.40b USD
EBIT TTM = 1.26b USD
EBITDA TTM = 1.29b USD
Long Term Debt = 2.10b USD (from longTermDebt, last quarter)
Short Term Debt = 74.4m USD (from shortTermDebt, last quarter)
Debt = 2.17b USD (Calculated: Short Term 74.4m + Long Term 2.10b)
Net Debt = -55.8m USD (from netDebt column, last quarter)
Enterprise Value = 8.93b USD (6.88b + Debt 2.17b - CCE 130.2m)
Interest Coverage Ratio = 39.80 (Ebit TTM 1.26b / Interest Expense TTM 31.5m)
FCF Yield = 5.49% (FCF TTM 490.3m / Enterprise Value 8.93b)
FCF Margin = 5.83% (FCF TTM 490.3m / Revenue TTM 8.40b)
Net Margin = 10.75% (Net Income TTM 903.3m / Revenue TTM 8.40b)
Gross Margin = 24.11% ((Revenue TTM 8.40b - Cost of Revenue TTM 6.38b) / Revenue TTM)
Tobins Q-Ratio = 1.86 (Enterprise Value 8.93b / Book Value Of Equity 4.80b)
Interest Expense / Debt = 0.64% (Interest Expense 13.8m / Debt 2.17b)
Taxrate = 23.31% (269.5m / 1.16b)
NOPAT = 962.9m (EBIT 1.26b * (1 - 23.31%))
Current Ratio = 11.35 (Total Current Assets 6.78b / Total Current Liabilities 597.5m)
Debt / Equity = 0.36 (Debt 2.17b / last Quarter total Stockholder Equity 6.06b)
Debt / EBITDA = 1.68 (Net Debt -55.8m / EBITDA 1.29b)
Debt / FCF = 4.43 (Debt 2.17b / FCF TTM 490.3m)
Total Stockholder Equity = 5.89b (last 4 quarters mean)
RoA = 9.56% (Net Income 903.3m, Total Assets 9.45b )
RoE = 15.33% (Net Income TTM 903.3m / Total Stockholder Equity 5.89b)
RoCE = 15.71% (Ebit 1.26b / (Equity 5.89b + L.T.Debt 2.10b))
RoIC = 12.03% (NOPAT 962.9m / Invested Capital 8.00b)
WACC = 7.42% (E(6.88b)/V(9.06b) * Re(9.61%)) + (D(2.17b)/V(9.06b) * Rd(0.64%) * (1-Tc(0.23)))
Shares Correlation 3-Years: -83.97 | Cagr: -0.99%
Discount Rate = 9.61% (= CAPM, Blume Beta Adj.)
[DCF Debug] Terminal Value 72.63% ; FCFE base≈603.3m ; Y1≈598.8m ; Y5≈626.0m
Fair Price DCF = 85.87 (DCF Value 8.49b / Shares Outstanding 98.8m; 5y FCF grow -1.47% → 3.0% )
EPS Correlation: -9.74 | EPS CAGR: -12.25% | SUE: -0.16 | # QB: 0
Revenue Correlation: 4.49 | Revenue CAGR: -0.08% | SUE: N/A | # QB: None
Additional Sources for TMHC Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle